| Lipid and transaminase concentrations after formulary conversion of Niaspan to Slo-Niacin. | |
| | |
MedLine Citation:
|
PMID: 21098376 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Lipid and transaminase levels after conversion from immediate-release niacin to extended-release niacin were evaluated. METHODS: All patients who had their medications converted from Niaspan to Slo-Niacin between March 2008 and January 2009 were considered for evaluation. Subjects who took =2000 mg of Niaspan were automatically converted to Slo-Niacin in a 1:1 dosing ratio conversion. Mean aspartate transaminase (AST) and alanine transaminase (ALT) levels and lipid values (low-density-lipoprotein [LDL] cholesterol, high-density-lipoprotein [HDL] cholesterol, and triglyceride levels) during Niaspan therapy were compared with the means of these values obtained after at least 90 days of Slo-Niacin therapy. Data were analyzed using the Wilcoxon rank-order test and frequency distributions. RESULTS: Of the 1172 patients who were identified as having had their Niaspan switched to Slo-Niacin after formulary conversion, 142 met the inclusion criteria for this study. The majority of the patients had a decrease or no change in AST (72.5%) and ALT (69%) levels after at least 90 days of Slo-Niacin therapy. None of the patients had transaminase levels greater than three times the upper limit of normal during Slo-Niacin therapy. Differences in AST, ALT, triglyceride, and LDL cholesterol levels were not statistically significant between Niaspan and Slo-Niacin. On the other hand, patients' mean HDL cholesterol level was significantly greater with Slo-Niacin therapy than with Niaspan (42 mg/dL versus 40 mg/dL, respectively; p < 0.05). CONCLUSION: Formulary conversion from Niaspan to Slo-Niacin resulted in a small but significant increase in HDL cholesterol concentration and no significant change in ALT or AST level. |
| | |
Authors:
|
Cristina Byrd; Kim A Mowrey |
Related Documents
:
|
16479026 - The role of lipid profile as a risk factor indicator for ischemic stroke at cipto mangu... 231466 - Cutaneous cholesterol and plasma lipoproteins in young subjects. 8310996 - Pyruvate supplementation of a low-cholesterol, low-fat diet: effects on plasma lipid co... 6957156 - Long-term use of gemfibrozil (lopid) in the treatment of dyslipidemia. 8876936 - Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein su... 12647966 - Effects of tallow in diets based on corn silage or alfalfa silage on digestion and nutr... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Volume: 67 ISSN: 1535-2900 ISO Abbreviation: Am J Health Syst Pharm Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-24 Completed Date: 2011-03-07 Revised Date: 2011-08-17 |
Medline Journal Info:
|
Nlm Unique ID: 9503023 Medline TA: Am J Health Syst Pharm Country: United States |
Other Details:
|
Languages: eng Pagination: 2038-42 Citation Subset: IM |
Affiliation:
|
James A. Haley Veterans Affairs Hospital, 13000 Bruce B. Downs Boulevard 119, Tampa, FL 33612, USA. cristina.byrd@va.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alanine Transaminase
/
blood,
drug effects Aspartate Aminotransferases / blood, drug effects Cholesterol, HDL / blood, drug effects Cholesterol, LDL / blood, drug effects Delayed-Action Preparations Dyslipidemias / drug therapy* Formularies, Hospital Humans Hypolipidemic Agents / administration & dosage, pharmacology* Niacin / administration & dosage, pharmacology* Retrospective Studies Statistics, Nonparametric Time Factors Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Delayed-Action Preparations; 0/Hypolipidemic Agents; 0/Triglycerides; 59-67-6/Niacin; EC 2.6.1.1/Aspartate Aminotransferases; EC 2.6.1.2/Alanine Transaminase |
| Comments/Corrections | |
Comment In:
|
Am J Health Syst Pharm. 2011 Jul 15;68(14):1294, 1297
[PMID:
21719588
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Probable interaction between warfarin and bee pollen.
Next Document: Use of blogs by pharmacists.